Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Shaping the Mechano-Pharmacological properties of Microparticles and Extracellular Vesicles for the Treatment of Osteoarthritis

Project description

Polymeric microparticles for the treatment of osteoarthritis

Osteoarthritis is the most common form of arthritis when the protective cartilage that cushions the ends of bones wears down over time, affecting millions of people worldwide. The disorder most commonly affects joints in hands, knees, hips and spine, and often leads to joint replacement surgery. Presently, the condition is not curable and only a symptomatic treatment is available. The EU-funded MEPHOS project aims to develop a novel integrated strategy for osteoarthritis treatment based on the intra-articular deposition of polymeric microplates providing simultaneous long-term pharmacological therapy and mechanical support. Polymeric microplates will provide continuous release of pain management medication and combination of molecules and biologicals, to prevent tissue degeneration while inducing regeneration processes. The project is a collaborative effort of seven European and American academic institutions and industrial partners for fabrication and biological and preclinical evaluation.

Objective

Osteoarthritis (OA) is a chronic disease involving the degeneration of articular cartilage and subchondral bone. It represents the single most common cause of disability in older adults. Being aging, obesity, trauma and gender risk factors for OA, its societal burden is rapidly rising. Across EU, over 40 million people are affected by OA. Current treatment options aim at modulating the symptoms rather than curing this chronic disease. Consequently, joint replacement continues to be ultimately the sole option. In this context, MEPHOS aims at realizing an integrated strategy for OA treatment based on the intra-articular deposition of hydrogel, polymeric microplates (uPLs) that could simultaneously provide a long-term pharmacological action and mechanical support. To this end, the uPL geometry and mechanical properties will be rationally selected to match the viscoelastic behaviour of cartilage and synovial fluid. Over the course of several weeks, uPLs will sustainably release clinically-approved molecules for pain management and novel small molecules and biologicals; including chemokine and metalloproteinase inhibitors to halt tissue degeneration; glycoproteins, growth factors and stem cell-derived extracellular vesicles to favour tissue regeneration. MEPHOS involves three EU Academic Institutions and a SME for uPL fabrication, and four US Academic Institutions for uPL biological and preclinical characterization. Through interdisciplinary and intersectoral secondments, this project will support the training of EU scientists on sophisticated in-vitro assays and three different preclinical OA models; foster the rational development of uPLs; and instil a translational research culture to bridge preclinical-clinical boundaries. The inclusion of a SME and the Stanford SPARK Translation program documents MEPHOS ambition to develop technologies that could hit the clinic and an industrial market, which is predicted to growth from $1.6 billion in 2016 to $3.5 billion by 2026.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-MSCA-RISE-2019

See all projects funded under this call

Coordinator

FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 372 600,00
Address
VIA MOREGO 30
16163 GENOVA
Italy

See on map

Region
Nord-Ovest Liguria Genova
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 395 600,00

Participants (4)

Partners (5)

My booklet 0 0